SteadyMed to Present at the 2016 JMP Securities Life Sciences Conference
June 21 2016 - 9:00AM
SteadyMed Ltd. (Nasdaq:STDY), a specialty pharmaceutical company
focused on the development of drug product candidates to treat
orphan and high-value diseases with unmet parenteral delivery
needs, today announced that Jonathan M. N. Rigby, President and
Chief Executive Officer, will present at the 2016 JMP Securities
Life Science Conference on Wednesday, June 22, 2016. During
the presentation, Mr. Rigby will provide an overview and update on
the company's business.
Date: Wednesday, June 22,
2016Time: 2:30 pm ETLocation: New
York, NY
About SteadyMed
SteadyMed Ltd. is a specialty pharmaceutical company focused on
the development of drug products to treat orphan and high-value
diseases with unmet parenteral delivery needs. The company's lead
drug product candidate is Trevyent®, a development stage drug
product that combines SteadyMed's PatchPump® technology with
treprostinil, a vasodilatory prostacyclin analogue to treat
pulmonary arterial hypertension (PAH). SteadyMed intends to
commercialize Trevyent in the U.S. and has signed an exclusive
license and supply agreement with Cardiome Pharma Corp. for the
commercialization of Trevyent in Europe, Canada and the Middle
East. SteadyMed has offices in San Ramon, California and Rehovot,
Israel. For additional information about SteadyMed please visit
www.steadymed.com.
Contacts:
Marylyn Rigby
Senior Director, Investor Relations and Marketing
925-272-4999
mrigby@steadymed.com
The Ruth Group
David Burke
(646) 536-7009
dburke@theruthgroup.com
STEADYMED LTD. (NASDAQ:STDY)
Historical Stock Chart
From Jun 2024 to Jul 2024
STEADYMED LTD. (NASDAQ:STDY)
Historical Stock Chart
From Jul 2023 to Jul 2024